Xencor Announces Change to Ultomiris® Royalty Revenue Forecast Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. informed Xencor, Inc. that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris ® in the United States and...

#XNCR Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

www.stocktitan.net/news/XNCR/xencor-announc...

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb ® drug candidates. “Xencor designs proteins that enable potential...

#XNCR Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

www.stocktitan.net/news/XNCR/xencor-highlig...

#XNCR Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

www.stocktitan.net/news/XNCR/xencor-announc...

Xencor Reports Third Quarter 2025 Financial Results Xencor (NASDAQ:XNCR) reported third quarter 2025 results and clinical updates on November 5, 2025. Q3 revenue was $21.0M vs $17.8M year-ago. Cash, cash equivalents and marketable debt securities were $633.9M at September 30, 2025 and the company expects to end 2025 with $570M–$590M, providing runway into 2028. Net loss was $6.0M, or $(0.08) per share, versus $(0.72) in Q3 2024. Other income increased to $41.5M driven by unrealized gains.Clinical: XmAb819 and XmAb541 showed early anti-tumor activity with planned recommended Phase 3 dose selection in 2026 and pivotal study starts in 2027; XmAb942 and plamotamab advanced into Phase 2b and Phase 1b studies, respectively.

#XNCR Xencor Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/XNCR/xencor-reports...

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma.

#XNCR Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

www.stocktitan.net/news/XNCR/xencor-present...

Leading Indicators, Tuesday October 21, 2025 – Crystal Equity Research

Small-cap stocks overbought with declining relative strength, Tue Oct 21st - #MIGI #APLM #XNCR #ANDE #ANAB #IDA #MUX - More: crystalequityresearch.com/leading-indi... - #smallcap

Xencor Reports Massive 82% Revenue Growth as 4 Key Drug Candidates Progress in Clinical Trials Strong Q2 results with $663.8M cash position and milestone payment from Incyte. Get details on XmAb819 cancer trial data coming Q4 2025. See clinical updates.

#XNCR Xencor Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/XNCR/xencor-reports...

Xencor Reports First Quarter 2025 Financial Results Xencor (NASDAQ:XNCR) reported its Q1 2025 financial results and business updates. The company's XmAb942 Phase 1 study showed promising results, supporting a 12-week maintenance dosing interval for ulcerative colitis treatment, with Phase 2b XENITH-UC study planned for H2 2025. Chief Development Officer Nancy Valente will transition to a senior advisory role in June 2025. Financially, Xencor reported Q1 2025 revenue of $32.7M (up from $16.0M in Q1 2024), with a net loss of $48.4M ($0.66 per share). The company maintains a strong cash position of $693.5M as of March 31, 2025, expecting to fund operations into 2028. Notable partnership developments include milestone payments from Incyte ($12.5M) and Vir Biotechnology ($2.0M).

#XNCR Xencor Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/XNCR/xencor-reports...

Can Xencor's $706M Cash Position Offset Growing Losses? Q4 Earnings Reveal Strategic Pivot Xencor posts $110.5M annual revenue with $232.6M net loss while advancing key clinical programs and securing $34M in partnership milestone payments.

#XNCR Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/XNCR/xencor-reports...

#XNCR Xencor to Participate at Upcoming Investor Conferences

www.stocktitan.net/news/XNCR/xencor-to-part...

NEWS: ( NASDAQ: #XNCR ) Xencor Announces Pricing of $175 Million Public Offering of Common Stock

#StockMarket #News

News; ( NASDAQ: #XNCR ) Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

#StockMarket #News